NPI 00X
Alternative Names: NPI-00XLatest Information Update: 12 Mar 2021
At a glance
- Originator Nacuity Pharmaceuticals
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Eye disorders
Most Recent Events
- 24 Feb 2021 Discontinued - Preclinical for Eye disorders in USA (unspecified route) (Nacutiy Pharmaceuticals pipeline, February 2021)
- 13 May 2020 Preclinical trials in Eye disorders in USA before May 2020 (unspecified route) (Nacuity pipeline, May 2020)